Spyre Therapeutics (SYRE) Other Accumulated Expenses (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Other Accumulated Expenses data on file, last reported at $165000.0 in Q1 2026.

• Quarterly Other Accumulated Expenses fell 55.53% year-over-year to $165000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165000.0 (down 55.53% YoY) and the FY2025 annual result came in at $179000.0, down 64.27% from the prior year.
• Other Accumulated Expenses retreated to $165000.0 in Q1 2026, from $179000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $726000.0 in Q1 2022 to a low of $165000.0 in Q1 2026.
• A 5-year average of $361400.0 and a median of $362000.0 in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 97.82% — and 2025, when it tumbled 67.68%.
• Tracing SYRE's Other Accumulated Expenses over 5 years: stood at $330000.0 in 2022, then jumped by 47.88% to $488000.0 in 2023, then increased by 2.66% to $501000.0 in 2024, then slumped by 64.27% to $179000.0 in 2025, then declined by 7.82% to $165000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $165000.0 (Q1 2026), $179000.0 (Q4 2025), and $170000.0 (Q3 2025), per Business Quant data.